Home » Newsletters » BioWorld Science

BioWorld Science

July 26, 2022

View Archived Issues

THR-beta agonists described by Shanghai Kunheng Pharmaceutical Technology, Kunming Pharmaceutical

Shanghai Institute of Materia Medica identifies new nagilactone derivatives

New SOS-1 inhibitors discovered at Chengdu Baiyu Pharmaceutical

Discovery of allosteric mutant-selective EGFR inhibitor for the treatment of NSCLC

Sarissa presents new DNA repair protein RAD51 homolog 1 inhibitors

New CDC7 inhibitors synthesized at Medshine Discovery

FDA accepts IND for HOOKIPA's arenaviral immunotherapy HB-300 for metastatic CRPC

Altamira Therapeutics to develop OligoPhore-based AM-411 for rheumatoid arthritis

PsychoGenics to evaluate preclinical antiseizure efficacy of IAMA's selective NKCC1 inhibitors

Oryzon collaborates with CMTRF to evaluate HDAC6 inhibitors for Charcot-Marie-Tooth disease

RNF31 as a novel therapeutic target for immunotherapy-refractory cancers

New compound advances anoctamin-1 inhibition for analgesia

Nonessential but critical, tyrosine plays key role in nutrient sensing

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...